

# VINOURELBINE

For first-line use in patients with EGFR wild-type NSCLC who are fit for chemotherapy, but not doublet chemotherapy (NICE CG121, April 2011)

Relapsed mesothelioma, where the patient is fit for further chemotherapy, but re-challenge with pemetrexed + platinum is not appropriate

Drug / Dosage:	Vinorelbine	30mg/m <sup>2</sup> (max 60mg)	IV	Day 1 and Day 8
Administration:	Vinorelbine diluted in 50ml 0.9% sodium chloride and infused over 5-10 minutes, running concurrently with 0.9% sodium chloride infusion. Flush the vein afterwards with a further 250ml saline infusion at a free flowing rate.			
Frequency:	3 weekly cycle; Day 1 and Day 8 Review subjective and objective response after each cycle Maximum 6 cycles			
Main Toxicities:	myelosuppression; peripheral neuropathy; alopecia (occasional) neuropathy-induced constipation; ovarian failure/infertility			
Anti-emetics:	mildly emetogenic			
Extravasation:	vesicant			
Regular Investigations:	FBC	Day 1 and Day 8		
	U&Es	Day 1		
	LFTs	Day 1		

## Dose Modifications

Haematological Toxicity:	Neutrophils < 1.5 x 10 <sup>9</sup> /l or Platelets < 100 x 10 <sup>9</sup> /l	Defer treatment. Check FBC in 1 week and delay next cycle for up to 2 weeks. Once recovered, give 100% dose.
	If significant myelotoxicity or more than 2 delays occur, consider giving on Days 1 and 15 on a 4-weekly schedule	
Hepatic Impairment:	If ALT/AST > 5 x ULN and / or bilirubin > 2 x ULN, it is suggested that the vinorelbine dose be reduced by 33% and haematological toxicity closely followed up.	
Neurotoxicity:	Vinorelbine should be discontinued in the event of Grade 3 - 4 peripheral neuropathy, or autonomic neuropathy causing constipation.	
Reference:	ELVIS Group, J of NCI, 1999; Vol 91 (1): 66-72 (NSCLC) Stebbing, J et al; Lung Cancer 2009; 63 (1): 94 – 97 (mesothelioma - with local decision to use NSCLC scheduling)	

Reason for Update: mesothelioma indication added; Hepatic Impairment section updated	Approved by Consultant: Dr V Ezhil
Version: 6	Approved by Lead Chemotherapy Nurse: V Mumford
Supersedes: Version 5	Date: 23.1.17
Prepared by: S Taylor	Checked by: C Tucker